Firms eye development of targeted cancer drugs

11/13/2012 | GenomeWeb Daily News (free registration)

AstraZeneca has teamed up with Foundation Medicine to identify genetic mutations in cancer-related tumor genes that may help predict a person's response or resistance to targeted treatments. Under terms of the deal, Foundation will get right of first negotiation to develop diagnostic tests. The deal will allow AstraZeneca to "identify tumor-specific defects and alterations that can be used for patient segmentation," said Susan Galbraith, vice president and head of AstraZeneca's Oncology Innovative Medicines Unit.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ